Intranasal esketamine use in bipolar disorder: A case report
Courtney Skriptshak, Ashley Reich
Mental Health Clinician July 1, 2021 DOI: 10.9740/mhc.2021.07.259 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | Patient diagnosed with bipolar disorder without recent history of manic or hypomanic episodes |
| Interventions | intranasal esketamine mood stabilizer therapy |
| Topics | Esketamine |
| Citations | 11 |
| Key findings | Intranasal esketamine in combination with mood stabilizer therapy may be safe in a patient with bipolar disorder without recent manic or hypomanic episodes. |
Abstract
Abstract Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The manufacturer of intranasal esketamine states that it “has not been studied, and is not indicated, for patients with bipolar disorder.” Antidepressants are commonly associated with having the potential to induce rapid cycling in patients with bipolar disorder, though the mechanism is not fully understood. This case report demonstrates the potential safety of intranasal esketamine in combination with mood stabilizer therapy in a patient diagnosed with bipolar disorder without recent history of manic or hypomanic episodes.